| Literature DB >> 29720270 |
Javad Aghazadeh-Attari1, Kazhal Mobaraki2, Jamal Ahmadzadeh2, Behnam Mansorian3, Iraj Mohebbi4.
Abstract
OBJECTIVE: The present study applied the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement to observational studies published in prestigious occupational medicine and health journals.Entities:
Keywords: Authors; Editors; Journals; Observational studies; Occupational medicine and health; Reviewers; STROBE statement
Mesh:
Year: 2018 PMID: 29720270 PMCID: PMC5932818 DOI: 10.1186/s13104-018-3367-9
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Top four occupational medicine and health journals and impact factor and STROBE endorsement
| Scientific journal ranking | Full journal title (NLM title abbreviation) | Impact factor in 2016 | Endorse STROBE? |
|---|---|---|---|
| (Q1) | Scandinavian Journal of Work, Environment and Health (Scand J Work Environ Health) | 4.071 | Yes |
| (Q1) | Occupational and Environmental Medicine (Occup Environ Med) | 3.912 | Yes |
| (Q1) | Journal of Occupational and Environmental Medicine (J Occup Environ Med) | 1.861 | No |
| (Q1) | American Journal of Industrial Medicine (Am J Ind Med) | 1.732 | No |
Percentage of items in the STROBE checklist which were addressed in cohort, case control, and cross-sectional studies published in four top scientific occupational journals in 2017
| Item | Recommendation | Reported n (%) | Not reported n (%) | Not applicable n (%) |
|---|---|---|---|---|
| Title and abstract | ||||
| 1a | Indicate the study’s design with a commonly used term in the title or the abstract | 39 (65.0) | 21 (35.0) | 0 (0.0) |
| 1b | Provide in the abstract an informative and balanced summary of what was done and what was found | 45 (75.0) | 15 (25.0) | 0 (0.0) |
| Introduction | ||||
| 2 | Explain the scientific background and rationale for the investigation being reported | 60 (100.0) | 0 (0.0) | 0 (0.0) |
| 3 | State specific objectives, including any pre-specified hypotheses | 53 (88.3) | 7 (11.7) | 0 (0.0) |
| Methods | ||||
| 4 | Present key elements of study design early in the paper | 31 (51.7) | 29 (48.3) | 0 (0.0) |
| 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 54 (90.0) | 6 (10.0) | 0 (0.0) |
| 6a | Give the eligibility criteria | 51 (85.0) | 7 (11.7) | 2 (3.3) |
| 6b | Describe methods of follow-up | 56 (93.3) | 4 (6.7) | 0 (0.0) |
| 6c | Give matching criteria | 7 (11.7) | 3 (5) | 50 (83.3) |
| 6d | Give number of exposed and unexposed in matched studies | 4 (6.7) | 4 (6.7) | 52 (86.7) |
| 7a | Clearly, define all outcomes | 60 (100.0) | 0 (0.0) | 0 (0.0) |
| 7b | Clearly, define all exposures | 53 (88.3) | 6 (10.0) | 1 (1.7) |
| 7c | Clearly, define all predictors | 55 (91.7) | 3 (5.0) | 2 (3.3) |
| 7d | Clearly, define all potential confounders | 41 (68.3) | 19 (31.7) | 0 (0.0) |
| 7e | Clearly, define all effect modifiers | 25 (41.7) | 35 (58.3) | 0 (0.0) |
| 8a | give sources of data | 60 (100.0) | 0 (0.0) | 0 (0.0) |
| 8b | details of methods of assessment (measurement) | 52 (86.7) | 8 (13.3) | 0 (0.0) |
| 9 | Describe any efforts to address potential sources of bias | 20 (33.3) | 40 (66.7) | 0 (0.0) |
| 10 | Explain how the study size was arrived at | 21 (35.0) | 22 (36.7) | 17 (28.3) |
| 11 | If applicable, describe which groupings were chosen and why | 46 (76.7) | 9 (15.0) | 5 (8.3) |
| 12a | Describe all statistical methods, including those used to control for confounding | 60 (100) | 0 (0.0) | 0 (0.0) |
| 12b | Describe all statistical software | 38 (63.3) | 22 (36.7) | 0 (0.0) |
| 12c | Describe any methods used to examine subgroups and interactions | 13 (21.7) | 45 (75.0) | 2 (3.3) |
| 12d | Explain how missing data were addressed | 29 (48.3) | 29 (48.3) | 2 (3.3) |
| 12e | If applicable, explain how loss to follow-up was addressed | 23 (38.3) | 24 (40) | 13 (21.7) |
| 12f | Describe any sensitivity analyses | 5 (8.3) | 55 (91.7) | 0 (0.0) |
| Results | ||||
| 13a | Report numbers of individuals at each stage of study | 28 (46.7) | 26 (43.3) | 6 (10.0) |
| 13b | Give reasons for non-participation at each stage | 4 (6.7) | 56 (93.3) | 0 (0.0) |
| 13c | Consider use of a flow diagram | 28 (46.7) | 32 (53.3) | 0 (0.0) |
| 14a | Give characteristics of study participants | 44 (73.3) | 16 (26.7) | 0 (0.0) |
| 14b | Indicate number of participants with missing data for each variable of interest | 8 (13.3) | 48 (80.0) | 4 (6.7) |
| 14c | Summarise follow-up time (e.g., average and total amount) | 21 (35.0) | 38 (63.3) | 1 (1.7) |
| 15 | Report numbers of outcome events or summary measures | 60 (100.0) | 0 (0.0) | 0 (0.0) |
| 16a | Give unadjusted estimates | 36 (60.0) | 24 (40.0) | 0 (0.0) |
| 16b | Give confounder-adjusted estimates | 26 (43.3) | 34 (56.7) | 0 (0.0) |
| 16c | Give estimates precision/confidence interval | 54 (90.0) | 6 (10.0) | 0 (0.0) |
| 16d | Report category boundaries when continuous variables were categorized | 48 (80.0) | 4 (6.7) | 8 (13.3) |
| 16e | If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | 14 (23.3) | 34 (56.7) | 12 (20.0) |
| 17 | Report other analyses done—e.g. analyses of subgroups and interactions and sensitivity analyses | 14 (23.3) | 46 (76) | 0 (0.0) |
| Discussion | ||||
| 18 | Summarise key results with reference to study objectives | 60 (100.0) | 0 (0.0) | 0 (0.0) |
| 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 53 (88.3) | 7 (11.7) | 0 (0.0) |
| 20a | Give a cautious interpretation of results considering objectives | 60 (100.0) | 0 (0.0) | 0 (0.0) |
| 20b | Explain results from similar studies | 60 (100.0) | 0 (0.0) | 0 (0.0) |
| 21 | Discuss the generalisability (external validity) of the study results | 46 (76.7) | 14 (23.3) | 0 (0.0) |
| Other information | ||||
| 22 | Give the source of funding and the role of the funders for the present study | 56 (93.3) | 4 (6.7) | 0 (0.0) |
| 1–22 | Total | 63.74 | 29.70 | 6.56 |
The STROBE statement is the guidelines for reporting observational studies, defined as Strengthening the Reporting of Observational Studies in Epidemiology
Fig. 1The overview of study design. STROBE checklist of items was addressed in prestigious scientific occupational medicine and health journals, 2016–2017